Drug Profile
ATA 274
Alternative Names: ATA274Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Atara Biotherapeutics
- Class Antineoplastics; Antivirals; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Glioblastoma in USA (Parenteral)